Five peptides dominate healing protocols: BPC-157, TB-500, GHK-Cu, KPV and thymosin alpha-1. None is approved by the US Food and Drug Administration for healing anything, and the order people rank them in is close to the reverse of the order the published evidence supports. BPC-157 is the most bought, and its entire musculoskeletal-injury record is 35 animal studies plus a single uncontrolled phone survey of 16 knee-pain patients; the only other human data are two uncontrolled pilot studies in unrelated conditions. GHK-Cu, which has the most human data on tissue repair of the five, was tested as a skin cream and a wound gel rather than as the injection people buy. What each one was measured doing, in which tissue, by which route, is the comparison that holds up.
Four of these five compounds have never been tested in a person for an injury like yours, and the fifth was tested as a cream. BPC-157, TB-500, GHK-Cu, KPV and thymosin alpha-1 act at different points in a repair, in different tissues, and the research behind each one differs in kind rather than in quantity. Sort the five by how much human evidence exists and the one everybody buys, BPC-157, lands fourth. Run the most popular stack against its own halves, as one 2026 rat experiment did, and the combination beat neither half.
What are healing peptides?
Healing peptides are short chains of amino acids, the same building blocks proteins are made from, most of them copies of fragments the body already makes, sold as freeze-dried powder and injected. The word healing does a lot of work in that sentence. A cut closing, a tendon regaining load tolerance, a gut lining sealing and an immune system recovering after an illness are four different biological jobs with four different bottlenecks. A compound with evidence in one of them has no automatic claim on the others, which is why lumping these five into one list misleads.
What peptides are best for healing? The whole field on one screen
The table below is ordered by how much human evidence exists for each compound, not by how popular it is. That ordering puts BPC-157, the compound most people arrive here looking for, in fourth place. For every row, almost none of that human evidence is about an injury.
| Compound | What it is | Strongest human evidence that exists | People studied | Route tested in humans | Evidence tier |
|---|---|---|---|---|---|
| GHK-Cu | A copper-carrying chain of three amino acids found naturally in human blood | A randomised trial of a cream on facial skin after CO2 laser resurfacing, which found no objective benefit 5, plus a multicentre randomised placebo-controlled trial of a gel on diabetic neuropathic ulcers, where median ulcer closure reached 98.5% against 60.8% for the vehicle gel 13 | 13 in the facial trial; the ulcer trial ran across several centres and reports no total in its abstract | Cream and gel on the skin. No published human trial has ever injected it | Randomised human data, all of it topical |
| Thymosin alpha-1 | A 28-amino-acid peptide made by the thymus, the gland that trains immune cells | Licensed as a prescription medicine outside the United States for hepatitis B and C and used as an immune add-on, with none of that work about tissue repair 15 | Hepatitis, sepsis and oncology trial populations, not injury populations | Injection under the skin | Approved elsewhere, never approved in the United States, and for a different job |
| TB-500 | A 7-amino-acid fragment copied out of the middle of thymosin beta-4, a 43-amino-acid protein | A phase 2 trial of the full protein (RGN-259, thymosin beta-4 0.1% eye drops) for severe dry eye, which reduced discomfort by 35.1% and corneal staining by 59.1% against placebo drops 4 | 9 (dry eye, and using the full protein rather than the fragment) | Eye drops; topical treatment for leg ulcers | Randomised, but different molecule and different tissue |
| BPC-157 | A 15-amino-acid chain copied from part of a protein in stomach fluid | A retrospective phone survey at one Florida clinic: 16 patients were called and asked to recall their knee pain, 12 of whom had received BPC-157 alone and 11 of those reported improvement, which the systematic review reads as 7 of the 12 reporting relief lasting more than six months. No control group, no imaging, no validated pain scale 12 | 16 (knee pain, recalled 6 to 12 months later) | Injection into the knee joint | Animal evidence only, for efficacy 1 |
| KPV | 3 amino acids snipped off the end of a natural anti-inflammatory hormone | None. The work is mouse colitis and human gut cell lines in a dish 714 | 0 | Never tested in a human study | Preclinical only |
A single ranking would hide the thing that decides whether any of these helps a particular person: which stage of a repair has stalled, and whether the compound has ever been measured acting at that stage.
This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. HSS Journal, 2025
Level IV and level V are the two weakest tiers of clinical evidence: case series without a comparison group, and expert opinion. The same review recorded that BPC-157 is broken down in the liver, has a half-life under 30 minutes and is cleared by the kidneys, and stated plainly that no clinical safety data were found. 1
Compound by compound, with an honest verdict on each
BPC-157: the broadest animal record, and essentially no human efficacy record
BPC-157 has the deepest animal literature of any compound in this category. Rat studies report faster healing in cut Achilles tendons, torn quadriceps, damaged ligaments, crushed muscle and irritated stomach lining, and the results are unusually consistent for a compound of this kind. The mechanism described in that work is a plumbing one: tendons and ligaments heal slowly because very little blood reaches them, and BPC-157 is reported to widen existing vessels and encourage new ones to grow into the injured area. The systematic review summarises that preclinical picture as BPC-157 increasing growth hormone receptor expression and several pathways involved in cell growth and new vessel formation while reducing inflammatory signals, with improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries in animals. 1
The human record is three uncontrolled pilot studies totalling roughly thirty people, with the same first author on all three, covering knee pain, interstitial cystitis and an intravenous safety check. None had a control group, and only the knee study involved an injury. The knee data are also read two ways: the primary paper reports 11 of 12 patients improving, while the systematic review records 7 of the 12 reporting relief lasting more than six months. 12 A 2025 narrative review of BPC-157 for musculoskeletal healing summarised the position as human data being extremely limited. 8 The first randomised, double-blind, placebo-controlled trial for an actual injury started recruiting in February 2026: 120 people with an acute grade II hamstring strain, 14 days of dosing alongside standard rehab, with time to unrestricted sport and MRI-measured injury volume as the endpoints. 11 Until that reads out, nobody can honestly tell you what BPC-157 does to a human tendon.
Verdict on BPC-157: the most researched compound here in animals and the least proven in people. Mechanism, reported side effects and how to read a certificate of analysis for it sit on the <a href="/peptides/bpc-157">BPC-157 monograph</a>; the ranges people report, and why they are not derived from the rat studies, are on the <a href="/learn/bpc-157-dosage-guide">BPC-157 dosage guide</a>.
TB-500: a fragment sold on trials that used the whole protein
TB-500 is seven amino acids long. Every human trial people cite in support of it used thymosin beta-4, the full 43-amino-acid protein it was cut out of. The best of those trials is a phase 2 study of RGN-259, thymosin beta-4 0.1% eye drops, in nine patients with severe dry eye who dosed six times daily; at day 56 the treated eyes had 35.1% less discomfort and 59.1% less corneal staining, a dye test of surface damage to the eye, than the placebo drops. 4 That is real randomised evidence, and it is about eyes, using drops, with a different molecule.
The human trials everyone cites for TB-500 used full thymosin beta-4, a 43-amino-acid protein. TB-500 is a seven-amino-acid piece of it, and no human trial has tested the piece for a tendon or muscle injury.
TB-500 does have one distinction nothing else here can claim. In the only published experiment that compared these compounds directly, TB-500 was the arm that reached statistical significance. Verdict on TB-500: the evidence is thinner than BPC-157's in volume but points more consistently in one direction on tendon biomechanics, and the molecule-versus-protein confusion means two vials with identical labels can hold different things. What is in a vial labelled TB-500, and how to tell, is set out on the <a href="/peptides/tb-500">TB-500 monograph</a>, with reported ranges on the <a href="/learn/tb-500-dosage-protocol">TB-500 dosage protocol</a> page. TB-500 is prohibited in sport at all times too, though under a different heading: the growth factors category (S2) rather than the non-approved substances category (S0) that covers BPC-157. Like BPC-157 it is an unapproved investigational compound in the United States, restricted for pharmacy compounding, and not legal to sell for human consumption.
GHK-Cu: the most human repair data in the group, and the biggest gap between what was tested and what is sold
GHK-Cu carries a copper atom, and copper is the cofactor that the enzyme cross-linking collagen fibres cannot work without, which is the clearest mechanism of anything on this page. It also has the most human data on tissue repair here. The problem is what that data is about. The one randomised controlled trial of GHK-Cu on facial skin ran 13 patients for 12 weeks after CO2 laser resurfacing; blinded evaluators and computer analysis found no significant reduction in redness and no significant improvement in wrinkles or skin quality, and the only significant difference was how satisfied patients said they were. 5 The positive human result is a topical gel on diabetic neuropathic ulcers, where a multicentre randomised placebo-controlled trial reported median plantar ulcer closure of 98.5% against 60.8% for the vehicle gel, and a lower rate of ulcer infection. 13 Both results are about skin, applied to skin.
No published human trial has ever injected GHK-Cu by any protocol, which matters because injectable vials are what most people buy. A 2026 review in the American Journal of Sports Medicine reached the same conclusion for injuries specifically, reporting that no clinical data support GHK-Cu use for musculoskeletal conditions. 6 GHK-Cu products sold as cosmetics or supplements are not approved to treat wounds or any other condition. Verdict on GHK-Cu: the most human repair evidence of the five and the widest gap between the studied form and the sold form. The copper chemistry and what the ulcer trial does and does not transfer to are covered on the <a href="/peptides/ghk-cu">GHK-Cu monograph</a> and in <a href="/learn/how-ghk-cu-works">how GHK-Cu works</a>, with skin-specific choices on <a href="/learn/best-peptides-for-skin">best peptides for skin</a> and the condition itself on <a href="/peptides-for/skin-aging">peptides for skin aging</a>.
KPV: strong laboratory work, zero human studies
KPV is three amino acids long and it gets into cells through PepT1, a transporter in the lining of the small intestine that pulls short peptides inside and that becomes more active in the colon during inflammatory bowel disease. In human gut cell lines, tiny concentrations of KPV blocked NF-kB, a master inflammation switch inside the cell, along with a second inflammatory signalling route. KPV given in drinking water reduced two different chemically induced colitis models in mice. 7 A separate 2008 study found KPV still calmed colitis in mice whose melanocortin-1 receptor, the docking point KPV was assumed to act through, does not function, which undercuts the popular explanation that KPV works by binding that receptor. 14
There is no human study of KPV, and we found no published live-animal study of KPV applied to skin. The transporter that carries it into cells is a gut transporter, which is the plainest reason the evidence sits where it does. Verdict on KPV: mechanistically the tidiest story here and the least tested in a person. Detail on the <a href="/peptides/kpv">KPV monograph</a>, gut-specific choices on <a href="/learn/best-peptides-for-gut-health">best peptides for gut health</a>, and the conditions themselves on <a href="/peptides-for/gut-healing">gut healing</a> and <a href="/peptides-for/inflammation">inflammation</a>.
Thymosin alpha-1: an approved drug doing a different job
Thymosin alpha-1 is the only compound on this page that is an approved prescription medicine anywhere, licensed outside the United States for hepatitis B and C and used as an immune add-on, with trial populations running to thousands of patients across infection, sepsis and cancer. 15 It has never been approved in the United States, and none of its approvals anywhere are for tissue repair. It nudges the immune system rather than blocking or stimulating it bluntly. It earns a place on a healing list only in the narrow sense of recovering from a long illness rather than from a torn tendon, and pretending otherwise is how an approved-drug label gets borrowed for a claim nobody tested. Verdict on thymosin alpha-1: real regulatory standing elsewhere, wrong indication for an injury. Detail on the <a href="/peptides/thymosin-alpha-1">thymosin alpha-1 monograph</a>.
One verdict covers all five: none of them has earned the word works in a human injury. What differs is how far each one sits from that line, and in which direction. GHK-Cu was tested in the wrong form, TB-500 as the wrong molecule, thymosin alpha-1 for the wrong job, KPV never in a person at all, and BPC-157 is the most bought of the five on the strength of rats.
What differs between them: which stage of a repair they act on
Repair runs as a sequence, and a compound that helps at one point in that sequence does nothing for a person stuck at a different one. The stages below are the standard description of how soft tissue heals; the timings are approximate and overlap heavily, and the point of laying them out is to see where each compound has and has not been measured.
The four jobs hiding inside the word healing
That last stage is why a stalled injury belongs in front of a clinician rather than in a search bar. Condition-specific context lives on <a href="/peptides-for/tendonitis">peptides for tendonitis</a>, <a href="/peptides-for/injury-recovery">peptides for injury recovery</a> and <a href="/peptides-for/joint-pain">peptides for joint pain</a>; muscle recovery specifically is covered on <a href="/learn/best-peptides-for-muscle-recovery">best peptides for muscle recovery</a>.
Does stacking BPC-157 and TB-500 work better than either alone?
The BPC-157 plus TB-500 pairing is the most popular combination in this category, and the reasoning behind it is tidy: one compound brings the blood supply, the other moves repair cells through it, so they should cover the two biggest bottlenecks together. In 2026 it was tested. Bicer and colleagues cut and repaired the Achilles tendon in 32 rats, split them into four groups of eight (control, BPC-157 at 10 mcg/kg/day, TB-500 at 60 mcg/kg/day, and both), dosed into the abdominal cavity for four weeks, then pulled the tendons apart to see what they could take. The paper describes its TB-500 arm as synthetic thymosin beta-4, which does not make clear whether the seven-amino-acid fragment or the full protein was dosed, the same ambiguity this page flags for vials.
Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone.
TB-500 alone was the arm that reached statistical significance on maximum load to failure, and it had the best tendon architecture scores. BPC-157 alone improved numerically without reaching significance on total scores. The combination beat neither compound alone, though it did beat the untreated control on tendon architecture scores. 3 One rat study does not settle a question, but it is the only direct test that exists, and it points the opposite way from the protocol most people are running.
BPC-157 against TB-500, on what has been measured
How the two are scheduled together follows from that difference in claimed persistence rather than from any trial, and the evidence for and against it is weighed on <a href="/learn/tb-500-bpc-157-half-life">the BPC-157 and TB-500 half-life page</a>. The named version of the pairing, sold as the wolverine stack, has its own review.
The full breakdown of that stack, including the 2026 regulatory timeline and how the rat head-to-head changes the case for running both, sits on the <a href="/learn/wolverine-stack-2026-review">Wolverine stack review</a>. General principles for combining compounds are on <a href="/learn/how-to-build-peptide-stack">how to build a peptide stack</a>.
How long do healing peptides take to work, and what did the studies do?
There is no reliable human answer, because no controlled human trial has measured time to recovery for any of these compounds in an injury. What can be said is exactly what researchers gave, to what, for how long, and what they measured at the end. Everything below is reported research, not a protocol for anyone to follow.
| Study | Subjects | What was given | Route | Duration before measurement | What was measured |
|---|---|---|---|---|---|
| Bicer 2026, cut Achilles tendon 3 | 32 rats, four groups of 8 | BPC-157 10 mcg/kg/day; TB-500 60 mcg/kg/day; or both | Into the abdominal cavity | 4 weeks | Maximum load to failure, tendon architecture scores, collagen types I and III |
| Lee and Padgett 2021, knee pain 2 | 16 patients phoned at one Florida clinic, 12 on BPC-157 alone | Not standardised across patients | Injection into the knee joint | Recalled 6 to 12 months later for most patients | Patient recall of pain, with no validated scale and no imaging |
| Sosne 2015, severe dry eye 4 | 9 patients, randomised and double-masked | Thymosin beta-4 0.1% (RGN-259), the full protein | Eye drops, six times daily | 28 days of dosing, assessed to day 56 | Discomfort questionnaire, corneal staining, tear film measures |
| Miller 2006, facial skin 5 | 13 patients after CO2 laser resurfacing | GHK-Cu cream | Topical on the face | 12 weeks | Blinded evaluator scores and computer analysis of redness, wrinkles, skin quality |
| Mulder 1994, diabetic ulcers 13 | Multicentre, randomised, evaluator-blinded, placebo-controlled | GHK-Cu gel plus standardised wound care | Topical on the ulcer | Through to closure | Percentage of ulcer closure, rate of closure, ulcer infection rate |
| Dalmasso 2008, colitis 7 | Mice, plus human gut cell lines | KPV in drinking water; KPV at the tiny concentrations described above, in cell culture | Oral and cell culture | Across the colitis model course | Colitis severity, inflammation signalling inside cells |
| NCT07437547, recruiting 11 | 120 people planned, acute grade II hamstring strain | BPC-157 alongside standardised rehab | Under the skin, daily | 14 days of dosing | Time to unrestricted sport, MRI-measured injury volume at day 14 |
The rat protocols are dosed by body weight into the abdominal cavity, which is not the route or the basis anyone uses, so the numbers circulating online are not derived from these studies. Converting an animal mcg/kg figure straight into a human number is the single most common error in this category, and it is worked through on <a href="/learn/peptide-dosing-mistakes">peptide dosing mistakes</a>. The longest measurement window in the whole set is 12 weeks, on skin. How long people run these compounds and whether they cycle off is a separate question with no trial behind it either, and the reasoning is set out on <a href="/learn/peptide-cycling-protocol">the peptide cycling protocol page</a>.
The mechanistic case and the sceptical case are both worth hearing in full, so here is a sports medicine physician reading the BPC-157 literature himself.
And the counterweight, from someone who ran these compounds and came off them. Reading only the enthusiastic version of this subject is how people end up disappointed.
Why do peptides work for some people and do nothing for others?
"BPC-157 changed my life" and "BPC-157 did nothing for me" are both honest reports from people who bought what they believed was the same thing. The explanations are worth putting in order of how much they explain, because most sites put them in the reverse order.
- What was actually in the vial. Nothing here is regulated, so the compound may not have been the compound, or not at the amount on the label. This explains more variation than everything below it combined, and it is the only item on this list with hard numbers behind it, which are further down this page. 10
- Which stage of repair had stalled. A compound measured improving blood supply does nothing for someone whose problem is collagen being laid down badly at nine months. The stage decides the ceiling.
- Whether the injury was ever going to respond to anything injected. A full tendon rupture, a mechanical impingement or an unstable joint is a surgical or rehabilitation question, and no vial changes that.
- Time and load. Tendon remodelling runs over months, and the loading programme running alongside it does more measured work than anything on this page.
- The possibility that the compound does not do in people what the animal work suggests. That is the base rate for compounds at this stage of testing.
- Genetics, last, and smallest of the six.
What your genes do and do not tell you here
The most repeated genetic claim in this category is that a variant in NOS3, the gene for the enzyme that makes nitric oxide in blood vessel walls, blunts BPC-157 by reducing the blood-flow signal it is supposed to work through. The story traces back to a 2000 PNAS paper reporting that the Asp298 form of that enzyme gets cut inside cells lining blood vessels. 12 Four years later, a different group showed that the cutting was an artefact of how the samples had been prepared, prevented it by changing the buffer, and found no significant difference in enzyme activity between the two forms. 9 The confident percentage figures circulating on peptide sites descend from the version that was overturned.
There was no significant difference in enzyme activity between the two forms once the sample preparation artefact was removed.
Knowing your NOS3 variant (rs1799983, if you want to search your own raw data file) does not tell you to change anything about a compound, because no study has ever connected that variant to a response to any peptide. What it tells you is how to read the sites that say otherwise. Two other variants come up in this category and deserve the same handling. COL1A1 rs1800012 sits in the gene for type I collagen, the main rope fibre in tendon and ligament, and has been studied for injury risk rather than for peptide response. MMP3 rs679620 relates to how quickly damaged tissue gets cleared out before new tissue goes in. Both describe the raw material and the pace of a repair. Neither has been tested against a peptide in a person.
If someone is going to buy anyway, this is what fails most often
We are not telling anyone to buy these. They are unapproved drugs sold for research use only, and the safest option is not to. The information below exists because people buy them regardless, and the supply chain is where the measurable harm sits. An April 2026 preprint tested 6,441 grey-market peptide samples across 14 compounds and found 41.6% to 71.1% failing basic quality checks depending on which of two quality models was applied; in a 243-sample subset tested for endotoxin, the bacterial debris that causes fever and inflammation when injected, 15% carried measurable levels. It has not been peer reviewed, which is worth knowing about the most quoted number in this category. 10 Against failure rates like that, arguments about which compound is best are second-order.
- A batch-specific certificate of analysis from an independent laboratory, dated and matching the lot number on the vial you received, not a generic PDF from the product page.
- Both identity and purity on that certificate. A mass spectrometry result confirms the molecule is what the label says; a purity percentage says how much of the rest is something else.
- An endotoxin or sterility result, which is the test most vendors quietly omit and the one that matters for anything injected.
- Price tells you nothing about quality here. Two vials at the same price can hold different molecules, which is a live issue for TB-500 specifically, where the fragment and the full protein are sold under one name.
- Storage before it reaches you and after. These arrive as freeze-dried powder, which is stable cold and degrades with heat and repeated temperature swings; once mixed with sterile water, it is a refrigerated, short-lived solution.
- Sterile technique if anything is injected, which is its own subject and not one to improvise.
Mixing and storage are covered on <a href="/learn/how-to-reconstitute-peptides">how to reconstitute peptides</a>, and injection technique and hygiene on the <a href="/learn/peptide-injection-hygiene-guide">peptide injection hygiene guide</a>. If you are new to the whole category, start at <a href="/learn/peptides-for-beginners">peptides for beginners</a> rather than here.
Are healing peptides legal in the US?
None of the five is an approved medicine in the United States for healing anything, and none may lawfully be marketed or sold for human consumption. BPC-157 was placed in Category 2 of the FDA's bulk drug substances list in 2023, which barred compounding pharmacies from using it. In April 2026 the FDA moved it off that list into a separate register of substances whose nominations were withdrawn, where it still sits today alongside every other compound on this page: thymosin beta-4 fragment (TB-500), injectable GHK-Cu, KPV and thymosin alpha-1 are all on it, and the FDA still publishes its safety concerns for each 16. Removal is not permission: it takes a substance off a restriction list without putting it on the positive list that legal compounding actually requires. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding BPC-157 and KPV to the 503A bulks list, against the position of the FDA's own reviewers 17. Those votes are advisory. They do not bind the FDA, the Department of Health and Human Services still has to act, and until a final rule appears in the Federal Register nothing has changed. Several peptides in this category are also covered by FDA import alerts, which is why grey-market shipments get seized at the border. Vendors label these as research chemicals not for human consumption, which is a labelling position rather than legal permission to take them. This section reflects the position in August 2026, the category moves quickly, and the FDA page linked below is the primary source.
What the compounding categories mean, what the July vote could still change, and why none of it makes any of these an approved medicine are set out on <a href="/learn/are-peptides-legal-us-2026">are peptides legal in the US in 2026</a>.
Link · HSS Journal, 2025Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewThe systematic review this page is built on. 544 articles screened, 36 included, 35 of them preclinical. Free full text.pubmed.ncbi.nlm.nih.gov Link · ClinicalTrials.gov, phase 2, recruitingBPC 157 for acute grade II hamstring strain repairThe first randomised, double-blind, placebo-controlled trial of BPC-157 for a musculoskeletal injury. 120 participants, 14 days of dosing, MRI and return-to-sport endpoints.clinicaltrials.gov Link · US Food and Drug AdministrationCertain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksThe primary source for the Category 2 bulk drug substances list and the April 2026 changes to it. Check it directly, since listings change.fda.govWhere people buy these
Where to get it
BPC-157
The one people take for injuries that will not heal
Save 10% at checkout with code tcwisiiu
Upload your raw DNA data and get all 39 peptides scored against a 144-marker panel covering 8 pharmacogenes and 15 pathways, with the strength of evidence graded honestly for each one, including where it is weak. Reports come back within 24 hours after human review. The report is educational and is not a diagnostic or clinical test. It does not predict whether any compound will work for you, does not recommend any compound, dose or protocol, and is not a substitute for advice from your own clinician. Human review means scientific and editorial quality control by our team; it is not a clinical consultation and creates no clinician-patient relationship.
Get your DNA report- Each one was measured doing a different job
GHK-Cu has randomised human trials and they are about skin cream and wound gel. TB-500's human trials used a different, larger molecule in the eye. BPC-157 has the deepest animal literature and no controlled human efficacy data. KPV has none in people at all. Comparing them on quantity of research hides the fact that they were measured doing different things in different tissues by different routes.
- The most popular stack lost to one of its own halves
BPC-157 plus TB-500 is the most-run combination in the category. The only experiment that ever tested it directly, 32 rats with a cut Achilles tendon dosed for four weeks, found the combination beat neither compound alone, and TB-500 on its own was the arm that reached statistical significance on load to failure.
- The stage that has stalled decides more than the vial does
Repair runs as a sequence: inflammation clears debris, blood supply grows in, cells arrive, collagen goes down, then the new tissue is remodelled to take load. A chronic injury is usually stuck at remodelling, months in, and that is the stage with no human trial behind any compound on this page.
Sources17
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal 2025;21(4):485-495.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine 2021;27(4):8-13.
- Bicer O, Adanir O, Guleryuz Y, Balci EC, Dincel YM, Yenigun MY, Aydin C, Bayrak BY. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Joint Diseases and Related Surgery 2026;37(3):822-837.
- Sosne G, Dunn SP, Kim C. Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea 2015;34(5):491-496.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery 2006;8(4):252-259.
- Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Hatch GFR, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine 2026;54(1):223-229.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134(1):166-178.
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine 2025;18(12):611-619.
- McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics 2004;14(12):831-839.
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprint, not peer reviewed, posted 24 April 2026.
- BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov NCT07437547, phase 2, recruiting, start date 2 February 2026, 120 participants planned.
- Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. PNAS 2000;97(6):2832-2835.
- Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration 1994;2(4):259-269.
- Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases 2008;14(3):324-331.
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones 2016;102:151-178.
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Category 2 list and the list of nominations subsequently withdrawn. Status checked August 2026.
- Todd S, Lawrence L. In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides. STAT News, 23 July 2026.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
Frequently asked questions
What are healing peptides?
Healing peptides are short chains of amino acids used in the hope of speeding up tissue repair, most of them copies of fragments the body already makes. BPC-157 is copied from a protein in stomach fluid, TB-500 from a protein that helps cells crawl toward damage, GHK-Cu from a copper-carrying molecule in blood, and KPV from the tail of a natural anti-inflammatory hormone. They are sold as freeze-dried powder in vials, mixed with sterile water and injected under the skin, and none of them is an approved medicine in the United States for healing anything.
What peptides are best for healing?
None of them is approved by the FDA for healing anything, so best here means best evidenced, not effective. Ordered by how much human evidence about tissue repair exists, GHK-Cu comes first, thymosin alpha-1 second, TB-500 third, BPC-157 fourth and KPV last, which is close to the reverse of how people usually rank them. Thymosin alpha-1 has more human data overall, since it is a licensed medicine outside the United States, but that work is about hepatitis and immune recovery rather than repair. GHK-Cu's randomised trials are a facial cream that found no objective benefit and a wound gel on diabetic ulcers that did improve closure, and the strongest TB-500 trial used the full 43-amino-acid protein as eye drops. BPC-157 has the broadest animal literature and no controlled human efficacy trial for any injury.
What are peptides for recovery, and do they help tendons heal?
The compounds people use for recovery are the same five: BPC-157, TB-500, GHK-Cu, KPV and thymosin alpha-1. For tendons specifically, no human trial of any of them exists. The best tendon evidence is a 2026 experiment in 32 rats with a surgically cut Achilles tendon, in which TB-500 significantly improved maximum load to failure and BPC-157 improved it without reaching significance. The first randomised, placebo-controlled human trial of BPC-157 for a musculoskeletal injury, in acute hamstring strain, only began recruiting in February 2026 and has not reported.
Does BPC-157 actually work in humans, or is it all rat studies?
The only systematic review of BPC-157 in orthopaedic sports medicine screened 544 articles from 1993 to 2024 and included 36, of which 35 were animal studies. The single clinical study was a retrospective phone survey at one Florida clinic: 16 patients were called and asked to recall their knee pain, 12 of them had received BPC-157 alone, and 11 of those reported improvement, which the systematic review reads more conservatively as 7 of the 12 reporting relief lasting more than six months. There was no control group, no imaging and no validated pain scale. The same review recorded that no clinical safety data were found.
Why do healing peptides work for some people and do nothing for others?
In order of how much they explain: what was in the vial, since a large share of grey-market samples fail basic quality checks; which stage of repair had stalled, since a compound measured improving blood supply does nothing for a collagen problem at nine months; whether the injury was ever going to respond to anything injected; time and the loading programme running alongside; and the real possibility that the compound does not do in people what animal work suggests. Genetics comes last, and no trial of any of these compounds has sorted responders from non-responders by genotype.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.